Endometrial serous adenocarcinoma
MONDO:0006196A high grade, aggressive adenocarcinoma arising from the endometrium. It is characterized by the presence of complex papillary patterns with cellular budding. Atypical mitoses, necrosis, and psammoma bodies may be present. It is classified as type II endometrial carcinoma and it is not associated with endometrial hyperplasia. It tends to invade deeply into the myometrium and spreads into the lymphatic vessels. Patients frequently present with spread of the tumor beyond the uterus at the time of diagnosis. The prognosis is usually poor.
Also known as: uterine serous adenocarcinoma, uterine serous carcinoma, body of uterus serous adenocarcinoma, endometrial serous adenocarcinoma, serous endometrial adenocarcinoma, uterine corpus serous adenocarcinoma, uterine papillary serous carcinoma, uterine serous papillary adenocarcinoma
2882 clinical trials for this condition and its sub-types, 36 tagged with Endometrial serous adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Immunotherapy combo shows promise for Hard-to-Treat ovarian cancer
Disease control CompletedThis phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 women with ovarian, fallopian tube, or peritoneal cancer that had come back or stopped responding to platinum-based chemotherapy. The study compared giving the drugs together versus one after …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Hormone blockers join forces against Treatment-Resistant endometrial cancer
Disease control CompletedThis phase II trial tests whether combining two hormone-blocking drugs — onapristone and anastrozole — can shrink tumors or slow cancer growth in women with hormone-receptor-positive endometrial cancer that has not responded to prior chemotherapy. Onapristone blocks progesterone …
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control CompletedThis phase II trial tested whether combining two drugs, pembrolizumab and olaparib, could help people with persistent or recurrent endometrial cancer or carcinosarcoma. The study enrolled 26 participants and looked at how many responded to treatment and what side effects occurred…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New cancer drug ZN-c3 shows early promise in solid tumor trial
Disease control CompletedThis early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…
Phase 1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for women with Hard-to-Treat uterine cancer?
Disease control CompletedThis study tested an experimental drug called ZN-c3 (azenosertib) in 92 women with a rare and aggressive type of uterine cancer that had come back or not responded to standard treatments. The goal was to see if the drug could shrink tumors and to check its safety. The drug is tak…
Phase 2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond bett…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Shorter radiation after hysterectomy shows promise for endometrial cancer
Disease control CompletedThis study tested a shorter course of pelvic radiation (about 1 week instead of the usual 5-6 weeks) given after hysterectomy for advanced endometrial cancer. The goal was to see if this shorter treatment causes fewer side effects while still controlling the cancer. The study inc…
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could a cancer drug shrink endometrial tumors?
Disease control CompletedThis phase 2 trial tested the drug cabozantinib in 102 women with endometrial cancer that had returned or spread. The drug works by blocking enzymes that help tumors grow and by cutting off their blood supply. Researchers measured how many patients saw their tumors shrink or stop…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Targeted radiation shows promise for recurrent gynecologic cancers
Symptom relief CompletedThis early-phase study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 15 women whose ovarian or uterine cancer had come back in a limited area. The main goal was to find the safest dose and check for side effects. Researchers also looked a…
Phase 1 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC